Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 23, Issue 8, 2010, Pages 794-805

  Chaiworapongsa, Tinnakorn ^a,b   Romero, Roberto ^a,b   Kusanovic, Juan P ^a,b   Savasan, Zeynep A ^a,b   Kim, Sun Kwon ^a   Mazaki Tovi, Shali ^a,b   Vaisbuch, Edi ^a,b   Ogge, Giovanna ^a   Madan, Ichchha ^a,b   Dong, Zhong ^a   Yeo, Lami ^a,b   Mittal, Pooja ^a,b   Hassan, Sonia S ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenic factor; congenital anomalies; fetal demise; preeclampsia; sFlt 1; soluble endoglin; soluble vascular endothelial growth factor receptor 1; stillbirth

Indexed keywords

ANGIOGENIC FACTOR; ANTIANGIOGENIC FACTOR; ENDOGLIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; AMNIOCENTESIS; AMNION FLUID ANALYSIS; ARTICLE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DELIVERY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; FETUS DEATH; HUMAN; IMMUNOASSAY; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; SOLUTIO PLACENTAE; AMNION FLUID; METABOLISM; MIDDLE AGED; PREGNANCY; YOUNG ADULT;

ADOLESCENT; ADULT; AMNIOTIC FLUID; ANTIGENS, CD; CROSS-SECTIONAL STUDIES; FEMALE; FETAL DEATH; HUMANS; MIDDLE AGED; PREGNANCY; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 77954702621     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767050903443467     Document Type: Article

References (64)

1. Fretts RC. Etiology and prevention of stillbirth. Am J Obstet Gynecol 2005;193:1923-1935.
2. Silver RM, Varner MW, Reddy U, Goldenberg R, Pinar H, Conway D, Bukowski R, Carpenter M, Hogue C, Willinger M, Dudley D, Saade G, Stoll B. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol 2007;196:433-444.
3. Silver RM. Fetal death. Obstet Gynecol 2007;109:153-167.
4. Smith GC, Fretts RC. Stillbirth. Lancet 2007;370:1715-1725.
5. Goldenberg RL, McClure EM, Belizan JM. Commentary: reducing the world's stillbirths. BMC Pregnancy Childbirth 2009;9 (Suppl 1):S1.
6. Blackwell S, Romero R, Chaiworapongsa T, Refuerzo J, Gervasi MT, Yoshimatsu J, Espinoza J, Berman S, Yoon BH. Unexplained fetal death is associated with changes in the adaptive limb of the maternal immune response consistent with prior antigenic exposure. J Matern Fetal Neonatal Med 2003;14:241-246.
7. Richani K, Romero R, Soto E, Espinoza J, Nien JK, Chaiworapongsa T, Refuerzo J, Blackwell S, Edwin SS, Santolaya-Forgas J, et al. Unexplained intrauterine fetal death is accompanied by activation of complement. J Perinat Med 2005;33:296-305.
8. Blackwell S, Romero R, Chaiworapongsa T, Kim YM, Bujold E, Espinoza J, Camacho N, Hassan S, Yoon BH, Refuerzo JS. Maternal and fetal inflammatory responses in unexplained fetal death. J Matern Fetal Neonatal Med 2003;14:151-157.
9. Gardosi J, Mul T, Mongelli M, Fagan D. Analysis of birthweight and gestational age in antepartum stillbirths. Br J Obstet Gynaecol 1998;105:524-530.
10. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442.
11. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439.
12. Cheung CY. Vascular endothelial growth factor: possible role in fetal development and placental function. J Soc Gynecol Investig 1997;4:169-177.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
14. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008;41:278-286.
15. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006;9:225-230.
16. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001;61:1207-1213.
17. Holderfield MT, Hughes CC. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res 2008;102: 637-652.
18. ten DP, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008;11:79-89.
19. Raab U, Lastres P, Arevalo MA, Lopez-Novoa JM, Cabanas C, de La Rosa EJ, Bernabeu C. Endoglin is expressed in the chicken vasculature and is involved in angiogenesis. FEBS Lett 1999;459:249-254.
20. Adam PJ, Clesham GJ, Weissberg PL. Expression of endoglin mRNA and protein in human vascular smooth muscle cells. Biochem Biophys Res Commun 1998;247:33-37.
21. O'Connell PJ, McKenzie A, Fisicaro N, Rockman SP, Pearse MJ, d'Apice AJ. Endoglin: a 180-kD endothelial cell and macrophage restricted differentiation molecule. Clin Exp Immunol 1992;90:154-159.
22. Perlingeiro RC. Endoglin is required for hemangioblast and early hematopoietic development. Development 2007;134: 3041-3048.
23. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649. (Pubitemid 43865232)
24. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998;179: 1539-1544.
25. Taylor RN, Grimwood J, Taylor RS,McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188: 177-182.
26. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999;106:1019-1022.
27. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348-2351.
28. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555-5563.
29. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658.
30. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683.
31. Chaiworapongsa T, Romero R, Espinoza J, Bujold E,Mee KY, Goncalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541-1547.
32. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
33. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
34. Chaiworapongsa T, Romero R, Gotsch F, Espinoza J, Nien JK, Goncalves L, Edwin S, Kim YM, Erez O, Kusanovic JP, et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 2008;21:41-52.
35. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, et al. The change in concentrations of angiogenic and antiangiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279-287.
36. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007;196:239-1236
37. Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006;195:255-259.
38. Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Norden- Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007;109:1368-1374.
39. Unal ER, Robinson CJ, Johnson DD, Chang EY. Secondtrimester angiogenic factors as biomarkers for future-onset preeclampsia. Am J Obstet Gynecol 2007;197:211-214.
40. Crispi F, Llurba E, Dominguez C, Martin-Gallan P, Cabero L, Gratacos E. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset preeclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;31:303-309.
41. Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 2008;32:871-876.
42. Chaiworapongsa T, Espinoza J, Gotsch F, Kim YM, Kim GJ, Goncalves LF, Edwin S, Kusanovic JP, Erez O, Than NG, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008;21:25-40.
43. Park CW, Park JS, Shim SS, Jun JK, Yoon BH, Romero R. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 2005;193:984-989.
44. Signore C, Mills JL, Qian C, Yu K, Lam C, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006;108:338-344.
45. Espinoza J, Romero R, Nien JK, Kusanovic JP, Richani K, Gomez R, Kim CJ, Mittal P, Gotsh F, Erez O, et al. A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). J Matern Fetal Neonatal Med 2006;19:607-613.
46. Kusanovic JP, Romero R, Espinoza J, Nien JK, Kim CJ, Mittal P, Edwin S, Erez O, Gotsch F, Mazaki-Tovi S, et al. Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol 2008;198:382-388.
47. Espinoza J, Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Nien JK, Kusanovic JP, Erez O, Bujold E, Goncalves LF, et al. Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med 2007;20:495-507.
48. Rana S, Rauh-Hain A, Karumanchi A, Thadhani R. Firsttrimester serum angiogenic factors and the risk of intrauterine fetal demise. Am J Obstet Gynecol 2007;197:S12.
49. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005;122:33-39.
50. Staff AC, Braekke K, Johnsen GM, Karumanchi SA, Harsem NK. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol 2007;197:176.
51. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E. Amniotic fluid - soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 2000;95:353-357.
52. Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, Jun JK. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2001;185:1130-1136. (Pubitemid 33097376)
53. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163-168.
54. Gonzalez RP, Gomez RM, Castro RS, Nien JK, Merino PO, Etchegaray AB, Carstens MR, Medina LH, Viviani PG, Rojas IT. A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000. Rev Med Chil 2004;132:1155-1165.
55. Scott SM, Buenaflor GG, Orth DN. Immunoreactive human epidermal growth factor concentrations in amniotic fluid, umbilical artery and vein serum, and placenta in full-term and preterm infants. Biol Neonate 1989;56:246-251.
56. Merimee TJ, Grant M, Tyson JE. Insulin-like growth factors in amniotic fluid. J Clin Endocrinol Metab 1984;59: 752-755.
57. Kurauchi O, Itakura A, Ando H, Kuno N, Mizutani S, Tomoda Y. The concentration of hepatocyte growth factor (HGF) in human amniotic fluid at second trimester: relation to fetal birth weight. Horm Metab Res 1995;27:335-338.
58. Heidari Z, Isobe K, Goto S, Nakashima I, Kiuchi K, Tomoda Y. Characterization of the growth factor activity of amniotic fluid on cells from hematopoietic and lymphoid organs of different life stages. Microbiol Immunol 1996;40:583-589.
59. Hirai C, Ichiba H, Saito M, Shintaku H, Yamano T, Kusuda S. Trophic effect of multiple growth factors in amniotic fluid or human milk on cultured human fetal small intestinal cells. J Pediatr Gastroenterol Nutr 2002;34:524-528.
60. Tranquilli AL, Giannubilo SR, Bezzeccheri V, Ciavattini A, Scagnoli C, Mazzanti L. Amniotic levels of nitric oxide and vascular endothelial growth factor in pregnancy with subsequent intrauterine fetal death. Eur J Obstet Gynecol Reprod Biol 2004;114:162-165. (Pubitemid 38622076)
61. Mulvihill SJ, Hallden G, Debas HT. Trophic effect of amniotic fluid on cultured fetal gastric mucosal cells. J Surg Res 1989;46:327-329.
62. Kong W, Yee LF, Mulvihill SJ. Hepatocyte growth factor stimulates fetal gastric epithelial cell growth in vitro. J Surg Res 1998;78:161-168.
63. Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N, Smith SK. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod 1994;51:524-530.
64. Clark DE, Smith SK, Sharkey AM, Charnock-Jones DS. Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod 1996;11:1090-1098.